Midregional pro-adrenomedullin plasma concentrations are blunted in severe preeclampsia

• Published in: Placenta (Eastbourne) Vol. 35; no. 9; pp. 780 - 783
• Main Authors: Matson, B.C, Corty, R.W, Karpinich, N.O, Murtha, A.P, Valdar, W, Grotegut, C.A, Caron, K.M
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.09.2014; Elsevier
• Subjects: Adrenomedullin; Adrenomedullin - blood; Adult; Biological and medical sciences; Biomarkers - blood; Case-Control Studies; Embryology: invertebrates and vertebrates. Teratology; Female; Fundamental and applied biological sciences. Psychology; Humans; Internal Medicine; Midregional pro-adrenomedullin; Obstetrics and Gynecology; Pre-Eclampsia - blood; Preeclampsia; Pregnancy; Protein Precursors - blood; Young Adult; Pregnancy; placental growth factor; MR-proADM; Preeclampsia; ROC; Adrenomedullin; endoglin; receiver operating characteristic; Midregional pro-adrenomedullin; PIGF; ENG; Biological fluid; Vertebrata; Mammalia; Pregnancy disorders; Severe; Pregnancy toxemia; Blood plasma
• ISSN: 0143-4004; 1532-3102
• DOI: 10.1016/j.placenta.2014.07.003

Abstract Levels of the peptide hormone adrenomedullin (AM) are elevated during normal pregnancy, but whether this differs during complications of pregnancy remains unresolved. AM can be quantified by measuring its pre-prohormone byproduct, midregional pro-adrenomedullin (MR-proADM). MR-proADM has shown prognostic value as a biomarker of heart failure, sepsis, and community-acquired pneumonia. Given the relevance of AM to pregnancy, we tested the hypothesis that MR-proADM provides a biomarker for preeclampsia. We find that MR-proADM plasma concentrations are blunted in severe preeclampsia and that MR-proADM is similarly effective as established biomarkers endoglin and placental growth factor at discriminating patients with severe preeclampsia from controls.